Clinical Scorecard: Evaluation of Changes in Optic Nerve Head and Macular Perfusion Before and After COVID-19 Onset

At a Glance

Key Highlights

• SARS-CoV-2 infects ocular tissues expressing ACE2 receptors and has been detected in retinal biopsies and tear fluid.
• COVID-19 causes retinal microvascular changes including reduced vessel density in optic nerve head and macular regions.
• OCTA enables non-invasive, high-resolution longitudinal assessment of retinal microcirculation before and after COVID-19 infection.

Guideline-Based Recommendations

Diagnosis

• Use polymerase chain reaction (PCR) testing to confirm COVID-19 infection.
• Perform comprehensive anterior and posterior segment ocular examinations including best-corrected visual acuity.
• Employ OCTA imaging to quantitatively assess retinal and optic nerve head vessel densities and foveal avascular zone.

Management

• Exclude patients with confounding ocular or systemic vascular diseases to isolate COVID-19 effects.
• Monitor recovered COVID-19 patients for retinal microvascular alterations using OCTA.
• Consider longitudinal OCTA imaging to detect early microvascular changes that may not be clinically evident.

Monitoring & Follow-up

• Repeat OCTA imaging at least one month post-COVID-19 recovery to evaluate changes in vessel density.
• Assess vessel density in superficial and deep capillary plexuses, optic nerve head, and radial peripapillary capillary network.
• Ensure image quality with signal strength >50 and absence of segmentation or motion artifacts.

Risks

• Potential for retinal vascular occlusions and microvascular damage due to COVID-19-induced hypercoagulability and endothelial dysfunction.
• Risk of vision-threatening complications secondary to microvascular impairment in optic nerve head and macula.

Patient & Prescribing Data

20 patients with baseline OCTA prior to COVID-19 infection who subsequently recovered from the disease

Significant reductions in optic nerve head and radial peripapillary capillary vessel densities were observed post-COVID-19, indicating microvascular impairment despite clinical recovery.

Clinical Best Practices

• Obtain baseline OCTA imaging in patients at risk to enable longitudinal comparison post-COVID-19 infection.
• Exclude confounding ocular and systemic diseases to accurately attribute microvascular changes to COVID-19.
• Use paired statistical analyses for within-subject longitudinal OCTA data to detect subtle microvascular alterations.
• Ensure rigorous image quality control with independent specialist review to validate OCTA measurements.

Related Resources & Content

• SARS-CoV-2 and ocular involvement
• OCTA in retinal microvascular assessment
• COVID-19 endothelial dysfunction and thrombosis
• Longitudinal OCTA changes in COVID-19 patients